Valuation: Black Diamond Therapeutics, Inc.

Market Cap 116M 100M 94.19M 85.66M 161M 11.1B 164M 1.1B 432M 5.56B 436M 426M 18.47B P/E 2026 *
-3.2x
P/E 2027 * -2.16x
Enterprise Value 116M 100M 94.19M 85.66M 161M 11.1B 164M 1.1B 432M 5.56B 436M 426M 18.47B EV / Sales 2026 *
20.9x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 week+3.59%
Current month+19.53%
1 month+11.60%
3 months-26.55%
6 months-9.01%
Current year-16.87%
1 week 1.95
Extreme 1.95
2.14
1 month 1.62
Extreme 1.62
2.14
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
3/20/26 Free

Director

6,919 0.0121%
1/21/26 Free

Chief Technology Officer

250,000 0.4388%
1/21/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.59%-26.81%-34.42% 116M
-1.90%+2.85%+62.82%+104.39% 70.07B
+12.82%+7.41%+43.67%+80.42% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+2.26%+0.09%+48.90%+11.90% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+3.23%+5.02%+38.77%-15.75% 18.75B
+0.38%-1.14%+16.94%+567.31% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +2.45%-0.44%+46.32%+176.76% 26.38B
Weighted average by Cap. +3.12%-1.40%+52.90%+164.62%

Financials

2026 *2027 *
Net sales 5.56M 4.8M 4.51M 4.1M 7.71M 531M 7.84M 52.83M 20.66M 266M 20.86M 20.41M 884M -
Net income -37.69M -32.55M -30.59M -27.82M -52.3M -3.6B -53.16M -358M -140M -1.8B -142M -138M -6B -62.63M -54.09M -50.83M -46.23M -86.92M -5.99B -88.35M -596M -233M -3B -235M -230M -9.97B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-08-17 $2.031 +0.54% 25,777
26-08-14 $2.020 0.00% 330,412
26-08-13 $2.020 -3.81% 489,102
26-08-12 $2.100 +0.48% 645,616
26-08-11 $2.090 +5.56% 812,736
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.020USD
Average target price
10.00USD
Spread / Average Target
+395.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock